20
Participants
Start Date
March 13, 2023
Primary Completion Date
August 22, 2026
Study Completion Date
August 22, 2026
Iohexol 350 Mg/mL Injectable Solution
Participants will be scanned with the digital breast tomosynthesis (DBT) system before and after the intravenous administration of iodinated contrast agent, iohexol 350mg I/mL at a dose of 1.5 mL/kg body weight. Images will be acquired of the breast of interest prior to the administration of contrast, followed by at approximately 2 minutes and 5 minutes after administration. For the purposes of this study, imaging will focus on a single breast to simplify data acquisition.
RECRUITING
University of North Carolina at Chapel Hill, Chapel Hill
UNC Lineberger Comprehensive Cancer Center
OTHER